CD5 deletion enhances the antitumor activity of adoptive T cell therapiesRuchi P. Patel, Patrizia Porazzi, Mathew G. Angelos et al.|Science Immunology|2024Cited by 45
Chimeric adenoviral (Ad5.F35) and listeria vector prime-boost immunization is safe and effective for cancer immunotherapyJohn C. Flickinger, Adam E. Snook|npj Vaccines|2022Cited by 16
CD8α Structural Domains Enhance GUCY2C CAR-T Cell EfficacyTrevor R. Baybutt, Adam E. Snook|Cancer Biology & Therapy|2024Cited by 9
Clinical Development of <i>Senza5TM CART5:</i> a Novel Dual Population CD5 CRISPR-Cas9 Knocked out Anti-CD5 Chimeric Antigen Receptor T Cell Product for Relapsed and Refractory CD5+ Nodal T-Cell LymphomasRuchi P. Patel, Marco Ruella, Guido Ghilardi et al.|Blood|2022Cited by 8